Study of the Cellular Response Induced After Vaccination Against the Hepatitis B Virus
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 10, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how the body responds to the hepatitis B vaccine, specifically looking at certain immune cells called T lymphocytes. Hepatitis B is a serious virus that affects millions of people worldwide, and while vaccination is the best way to prevent it, not everyone responds the same way. Researchers want to find out how many healthy adults show a specific type of T cell response after getting the vaccine and how this relates to the levels of antibodies produced, which are proteins that help fight off infections.
To participate in this study, you need to be at least 18 years old and must have had a blood test for hepatitis B done within four weeks before getting vaccinated. However, individuals who are pregnant, breastfeeding, or have certain chronic health conditions that affect their immune system will not be eligible. The trial is not yet recruiting participants, but once it starts, those who join will help researchers gain valuable insights into how the hepatitis B vaccine works, which could lead to improved vaccination strategies in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults ≥18 years
- • Pre-vaccination HBV serology carried out within 4 weeks prior to vaccination
- • Collection of no objection
- Exclusion Criteria:
- • Opposition of the person or inability to give opposition
- • Pregnant or breast-feeding women
- • Chronic illnesses affecting the individual's immune system (asplenia; hyposplenia; haematological cancer; auto-immune disease requiring immunosuppressive treatment, HIV infection).
- • Non-affiliation with a social security scheme, Universal Medical Coverage or any equivalent scheme
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported